New Chemistry Method Simplifies Late-Stage Modification of Drug Compounds
The technique is expected to find application not just in the pharmaceutical chemistry industry but also in a wide range of other chemical industries
LA JOLLA, Calif. – Nov. 22, 2017 – Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs. The technique, known as ligand-accelerated non-directed C–H functionalization, is expected to find application not just in the pharmaceutical chemistry industry but also in a wide range of other chemical industries. However, it should be particularly useful for altering complex candidate drug molecules to find versions with optimal therapeutic properties.
“One can use this new technology to modify a drug molecule at a late stage of synthesis, to improve the molecule’s properties without having to go back to change the synthesis from the beginning,” said study senior author Jin-Quan Yu, PhD, Frank and Bertha Hupp Professor in the Department of Chemistry at TSRI.
The new method, reported this week in the journal Nature, was developed by Yu’s laboratory in collaboration with scientists at Bristol-Myers Squibb, who are already applying the method in their drug development programs.
Jin-Quan Yu, PhD, Frank and Bertha Hupp Professor in the Department of Chemistry at TSRI.Photo courtesy of The Scripps Research InstituteYu is known for the many new methods he and his laboratory have devised for achieving a basic molecule-building operation known as C–H functionalization. The term refers to the removal of a hydrogen (H) atom from the carbon (C) backbone of an organic molecule and its replacement with a more reactive cluster of atoms known as a functional group. The latter is often the key to the molecule’s biological or other properties. C–H functionalization frequently involves a metal atom, such as palladium, that catalyzes the initial cleavage of the carbon–hydrogen bond.
Most of Yu’s recent advances in C–H functionalization have involved the use of a special functional group known as a directing group. A directing group becomes a part of the initial organic molecule (substrate) and effectively “directs” the C–H functionalization reaction to occur at the desired carbon–hydrogen bond on the substrate.
Directing-group C–H functionalizations can’t always be used, however. “For some substrates, there isn’t a suitable directing group, or there isn’t one within effective range of the C–H bond that is meant to be functionalized,” Yu said.
In such cases, there are often no good options. Metal catalysts in the absence of a directing group typically won’t interact with the targeted C–H bond strongly enough or selectively enough to do the job. The chemist may compensate for the lack of a directing group by using a relatively large amount of substrate molecules to statistically increase the interactions between metal catalyst and substrate molecules thereby enabling the C–H activation to proceed, but that is not practical—particularly for substrates that are themselves hard to produce in large quantities as only a small portion of the highly valuable substrate will be converted into the desired products.
To overcome this long-standing problem in the field of C–H activation, Yu and his team, including first author Peng Wang, a postdoctoral research associate in the Yu Laboratory, sought a special molecule that could serve as a “ligand.” In metal-catalyzed C–H functionalizations, a ligand molecule fastens to the metal atom in a way that enhances its reactivity with a targeted C–H bond.
In this case, investigations by Yu’s team ultimately led them to a ligand molecule called a 2-pyridone. Using a broad class of substrate molecules called arenes, they found that the 2-pyridone ligand greatly enhances palladium’s ability to make non-directed C–H functionalizations—so much so that the chemists were able to use normal rather than excess quantities of the arene substrate molecules.
Using the technique, Yu’s team modified a broad variety of arenes by adding functional groups from the olefin and carboxylic acid families of organic molecules. The products included modified versions of numerous molecules of interest to biologists and medicinal chemists: amino acid derivatives; the beacon molecule fluorescein; the plant-derived stimulant caffeine; the plant-derived antitumor compound camptothecin; and synthetic pharmaceuticals, including fenofibrate, gemfibrozil, diflunisal, viloxazine, and betaxolol.
Yu and colleagues found that the use of their 2-pyridone ligand didn’t merely accelerate the attachment of functional groups to substrate molecules. In some cases, it also altered the selectivity of these C–H functionalizations, favoring some sites on the molecule over others—much as a directing group does.
“Where these C–H functionalizations occur on substrate molecules is mostly dictated by their intrinsic charge properties and geometries, but we have shown here that for a few classes of arenes, the ligand also has the effect of enhancing the site-selectivity of these functionalizations,” Yu said.
Yu and his team have begun to study the detailed mechanisms by which the 2-pyridone ligand affects C–H functionalizations and hope to expand the application of ligand-accelerated non-directed C–H functionalization to other classes of organic molecule beyond arenes.
In addition to co-first authors Yu and Wang, other co-authors of the paper, “Ligand-accelerated non-directed C?H functionalization of arenes,” were Pritha Verma, Guoqin Xia, Jun Shi and Marcus E. Farmer of TSRI; and Jennifer X. Qiao, Shiwei Tao, Peter T. W. Cheng, Michael A. Poss and Kap-Sun Yeung of Bristol-Myers Squibb.
Support for the research came from the National Institutes of Health (grant NIGMS 2R01 GM102265) and Bristol-Myers Squibb.
About The Scripps Research Institute
The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including two Nobel laureates and 20 members of the National Academies of Science, Engineering or Medicine—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. In October 2016, TSRI announced a strategic affiliation with the California Institute for Biomedical Research (Calibr), representing a renewed commitment to the discovery and development of new medicines to address unmet medical needs. For more information, see www.scripps.edu.